Rx Pimecrolimus 1%
Pimecrolimus is a calcineurin inhibitor. It suppresses T-cell activation by binding to the intracellular protein FKBP-12 and complexes with calcineurin dependent proteins resulting in decreased calcineurin phosphatase activity and reduced downstream activation of T lymphocytes.
Indications: Second line topical treatment of moderate to severe OLP, MMP, PV.
Contraindications: Hypersensitivity to the drug or any component of the formulation. Fungal, viral or bacterial infections of the oral cavity or throat.
Warnings/Precautions: Avoid use on malignant or premalignant skin conditions. Limit sun and ultraviolet light exposure; use appropriate sun protection. Do not use on areas of active bacterial or viral infection. Avoid in patients with atopic dermatitis. Do not use in immunocompromised patients.
Drug interactions: No significant drug interactions reported. Fungal, viral or bacterial infections of the oral cavity or throat.
Dosage form – 1% cream.
Topical – Apply thin coating of cream to lesion 2 to 4 times per day. Do not eat or drink for 30 minutes.
Monitor efficacy: Improved oral comfort, lesion resolution.
Monitor toxicity: Mucosal thinning, burning, candida superinfection.
Length of treatment: As may be required to manage painful exacerbations of OLP.
Cessation of treatment: Topical regimens may be discontinued without tapering.
Instructions to the patient: Use only as instructed. Do not swallow.
For additional information see DailyMed